Business Context and Reporting Period
This Form 8-K was filed by Supernus Pharmaceuticals, Inc. on February 28, 2022. The filing serves to announce preliminary financial results for the fourth quarter and full year ended December 31, 2021, and to disclose modifications to executive compensation arrangements effective January 1, 2022.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained in a press release (Exhibit 99.1) which is incorporated by reference but not included in the provided text.
Material Changes and Executive Compensation
On February 22, 2022, the Board of Directors approved modifications to the compensation of six executive officers, effective January 1, 2022. The changes include base salary increases, 2021 bonuses, and equity grants (stock options, RSUs, and PSUs).
- Jack A. Khattar (CEO): Base salary increased to $913,500; awarded $887,400 bonus; granted 250,000 options and 125,000 PSUs.
- Timothy C. Dec (CFO): Base salary increased to $412,500; awarded $72,300 bonus; granted 25,000 options, 2,000 RSUs, and 3,000 PSUs. Bonus target increased to 45% of base salary.
- Padmanabh P. Bhatt (CSO): Base salary increased to $415,200; awarded $158,900 bonus; granted 18,000 options, 3,000 RSUs, and 3,000 PSUs.
- Jonathan Rubin (CMO): Base salary increased to $412,000; awarded $143,700 bonus; granted 25,000 options, 3,000 RSUs, and 3,000 PSUs. Bonus target increased to 40% of base salary.
- Tami T. Martin (SVP, Regulatory): Base salary increased to $346,300; awarded $129,700 bonus; granted 18,000 options, 3,000 RSUs, and 3,000 PSUs.
- Frank Mottola (SVP, Quality/IT): Base salary increased to $342,400; awarded $131,900 bonus; granted 18,000 options, 3,000 RSUs, and 3,000 PSUs.
Stock option exercise price is set at $32.20 per share. Equity awards generally vest over four years, with PSUs subject to performance goals.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding plans and strategies but does not provide specific financial guidance or numerical outlooks in the text provided. The Company directs investors to its Annual Report on Form 10-K and Quarterly Report on Form 10-Q for a detailed discussion of risk factors, including ordinary business operations and general economic conditions.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for the actual Q4 and full-year 2021 financial results (revenue, net income, cash flow) which are not detailed in this 8-K text.
- Verify the vesting schedules and performance metrics for the newly granted Performance Share Units (PSUs) in the full Award Agreement.
- Confirm the impact of the executive compensation increases on the company's future operating expenses and cash burn rate.
- Check the stock price relative to the $32.20 exercise price for the new option grants to assess immediate dilution or value.